comparemela.com
Home
Live Updates
FDA Grants Fast Track Status to MYTX-011 for NSCLC With cMET Overexpression : comparemela.com
FDA Grants Fast Track Status to MYTX-011 for NSCLC With cMET Overexpression
The FDA has granted fast track designation to MYTX-011 for use as a potential therapeutic option in patients with non–small cell lung cancer and cMET overexpression.
Related Keywords
Massachusetts ,
United States ,
Brian Fiske ,
International Conference On Molecular ,
Mythic Therapeutics ,
Massachusetts General Hospital ,
Molecular Targets ,
Lung Cancer ,
News ,
Metastatic Non Small Cell Lung Cancer ,
Nsclc ,
Mytx 011 ,
Fda ,
Fast Track ,
Cmet Overexpression ,
comparemela.com © 2020. All Rights Reserved.